Analysis of quinazoline and pyrido[2,3-d]-pyrimidine N9-C10 reversed-bridge antifolates in complex with NADP+ and Pneumocystis carinii dihydrofolate reductase

被引:19
作者
Cody, V
Galitsky, N
Luft, JR
Pangborn, W
Queener, SF
Gangjee, A
机构
[1] Hauptman Woodward Med Res Inst Inc, Buffalo, NY 14203 USA
[2] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA
[3] Duquesne Univ, Grad Sch Pharmaceut Sci, Div Med Chem, Pittsburgh, PA 15282 USA
来源
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY | 2002年 / 58卷
关键词
D O I
10.1107/S0907444902010442
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Structural studies of two ternary complexes of Pneumocystis carinii dihydrofolate reductase (pcDHFR) with the cofactor NADP(+) and potent antifolates, the N9-C10 reversed-bridge inhibitor 2,4-diamino-6-[N-(2',5'-dimethoxybenzyl)-N-methylamino]quinazoline (1) and its 30,50 -dimethoxypyrido[2,3d]pyrimidine analog (2), were carried out. Data for the monoclinic crystals were refined to 1.90 Angstrom resolution for the complex with (1) (R = 0.178) and to 2.1 Angstrom resolution for the complex with (2) (R = 0.193). The effect of the N9-C10 reversed-bridge geometry is to distort the bridge from coplanarity with the pyrido[2,3-d]pyrimidine or quinazoline ring system and to twist the C10 methylene conformation toward a gauche conformation. This change also influences the conformation of the methoxybenzyl ring, moving it away from a trans position. This change places the 5'-methoxy group deeper within the hydrophobic pocket made by Ile65, Pro66 and Phe69 of the pcDHFR active site. These results also revealed the first observation of an unusual conformation for the reversed-bridge geometry (C5-C6-N9-C10 torsion angle) in antifolate (2). The electron density is consistent with the presence of two models (conformers 2-1 and 2-2) that result from inversion of the geometry at N9. The four examples of N9-C10 reversed-bridge antifolates cluster in two conformations, with the structure of quinazoline (1) similar to that previously reported for its 20,50 -dimethoxypyrido[2,3-d]pyrimidine analog (3). The two conformers of (2) differ from these and each other by a twisted-bridge geometry that results in the dimethoxybenzyl ring occupying the same conformational space. Conformer 2-2 also has the N9-C10 reversed bridge perpendicular to the pyrido[2,3-d]pyrimidine plane, in contrast to the gauche-trans conformation normally observed. As a result of these changes, the N9 methyl probes conformational space in the active site not normally occupied by antifolate structures. The N9 methyl of conformer 2-2 makes close contacts to the conserved Leu25 as well as the hydroxyl O atoms of the nicotinamide ribose and Ser64, whereas the other three reversed-bridge conformers make weak hydrophobic contacts with Ile123, Thr61 and Ile65. These antifolates are ten times more selective for pcDHFR than the C9-N10 bridge parent trimetrexate. However, pyrido[2,3-d]pyrimidines (2) and (3) are three times more selective for pcDHFR than quinazoline (1) is for rat liver DHFR. These data suggest that the loss of hydrogen-bonding interactions with N8 is more important to potency than the interactions of the methoxybenzyl substituents.
引用
收藏
页码:1393 / 1399
页数:7
相关论文
共 19 条
[1]   PNEUMOCYSTIS-CARINII DIHYDROFOLATE-REDUCTASE USED TO SCREEN POTENTIAL ANTIPNEUMOCYSTIS DRUGS [J].
BROUGHTON, MC ;
QUEENER, SF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) :1348-1355
[2]   STRUCTURE OF PNEUMOCYSTIS-CARINII DIHYDROFOLATE-REDUCTASE TO 1.9-ANGSTROM RESOLUTION [J].
CHAMPNESS, JN ;
ACHARI, A ;
BALLANTINE, SP ;
BRYANT, PK ;
DELVES, CJ ;
STAMMERS, DK .
STRUCTURE, 1994, 2 (10) :915-924
[3]   Ligand-induced conformational changes in the crystal structures of Pneumocystis carinii dihydrofolate reductase complexes with folate and NADP+ [J].
Cody, V ;
Galitsky, N ;
Rak, D ;
Luft, JR ;
Pangborn, W ;
Queener, SF .
BIOCHEMISTRY, 1999, 38 (14) :4303-4312
[4]   Comparison of ternary complexes of Pneumocystis carinii and wild-type human dihydrofolate reductase with coenzyme NADPH and a novel classical antitumor furo[2,3-d]pyrimidine antifolate [J].
Cody, V ;
Galitsky, N ;
Luft, JR ;
Pangborn, W ;
Gangjee, A ;
Devraj, R ;
Queener, SF ;
Blakley, RL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1997, 53 :638-649
[5]  
CODY V, 1993, ADV EXP BIOL MED, P481
[6]   SETOR - HARDWARE-LIGHTED 3-DIMENSIONAL SOLID MODEL REPRESENTATIONS OF MACROMOLECULES [J].
EVANS, SV .
JOURNAL OF MOLECULAR GRAPHICS, 1993, 11 (02) :134-&
[7]   INCORPORATION OF FAST FOURIER-TRANSFORMS TO SPEED RESTRAINED LEAST-SQUARES REFINEMENT OF PROTEIN STRUCTURES [J].
FINZEL, BC .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1987, 20 :53-55
[8]   2,4-Diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases [J].
Gangjee, A ;
Vasudevan, A ;
Queener, SF ;
Kisliuk, RL .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (07) :1438-1446
[9]   Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents [J].
Gangjee, A ;
Vidwans, AP ;
Vasudevan, A ;
Queener, SF ;
Kisliuk, RL ;
Cody, V ;
Li, RM ;
Galitsky, N ;
Luft, JR ;
Pangborn, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3426-3434
[10]  
HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG